Balancing individual benefit against public health risk: The impact of cotrimoxazole prophylaxis in hiv-infected patients on antimicrobial resistance

American Journal of Tropical Medicine and Hygiene

Volumn 79, Issue 3, 2008, Pages 299-300

  Hamer, Davidson H ^a   Gill, Christopher J ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; EDITORIAL; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; OPPORTUNISTIC INFECTION;

EID: 51949092918     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2008.79.299     Document Type: Editorial

References (11)

1. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R, 1999. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353: 1463-1468.
2. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kogozi A, Nakanjako D, Wafula W, Quick R, 2004. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428-1434.
3. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P, 2006. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367: 1256-1261.
4. Gill CJ, Sabin LL, Tham J, Hamer DH, 2004. Reconsidering cotrimoxazole prophylaxis for HIV-exposed African infants. Bull World Health Organ 82: 1-7.
5. Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K, Williamson J, Shi YP, Feikin DR, Marston B, Brooks JT, Poe A, Zhou Z, Ochieng B, Mintz E, Slutsker L, 2008. Does co-trimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 79: 320-330.
6. Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M, Nsofwa M, Chalwe V, Mwananyanda L, Mukwamataba D, Malilwe B, Champo D, Macleod WB, Thea DM, Hamer DH, 2008. Effect of presumptive cotrimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology, and antibiotic resistance among Zambian infants. Bull World Health Organ (in press).
7. Ministry of Health, 2006. National Guidelines for Diagnosis, Treatment & Prevention of Malaria for Health Workers. Republic of Kenya, Nairobi: Ministry of Health.
8. Montanari MP, Cochetti I, Mingoia M, Varaldo PE, 2003. Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 2236-2241.
9. World Health Organization, 2005. Technical Updates on the In tegrated Management of Childhood Illness (IMCI). Evidence and Recommendations for Further Adaptations. Geneva, Switzerland: World Health Organization.
10. Ministry of Health, 2007. Kenya Integrated Management of Child hood Illness Guidelines, 2007. Nairobi, Kenya: Ministry of Health.
11. Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B, Pakistan Co-trimoxazole Study Group, 1998. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxicillin for pneumonia among children in Pakistan: randomised controlled trial. Lancet 352: 270-274.